These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 35169333)
21. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study. Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785 [TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study. Knuf M; Romain O; Kindler K; Walther U; Tran PM; Pankow-Culot H; Fischbach T; Kieninger-Baum D; Bianco V; Baine Y; Miller J Eur J Pediatr; 2013 May; 172(5):601-12. PubMed ID: 23307281 [TBL] [Abstract][Full Text] [Related]
23. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. Pace D; Khatami A; McKenna J; Campbell D; Attard-Montalto S; Birks J; Voysey M; White C; Finn A; Macloed E; Faust SN; Kent AL; Heath PT; Borrow R; Snape MD; Pollard AJ BMJ; 2015 Apr; 350():h1554. PubMed ID: 25832102 [TBL] [Abstract][Full Text] [Related]
24. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. Read RC; Dull P; Bai X; Nolan K; Findlow J; Bazaz R; Kleinschmidt A; McCarthy M; Wang H; Toneatto D; Borrow R Vaccine; 2017 Jan; 35(3):427-434. PubMed ID: 27912986 [TBL] [Abstract][Full Text] [Related]
25. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease. Dull PM; McIntosh ED Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895 [TBL] [Abstract][Full Text] [Related]
26. Parental awareness of Meningococcal B vaccines and willingness to vaccinate their teens. Basta NE; Becker AB; Li Q; Nederhoff D Vaccine; 2019 Jan; 37(4):670-676. PubMed ID: 30587431 [TBL] [Abstract][Full Text] [Related]
27. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination. van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167 [TBL] [Abstract][Full Text] [Related]
28. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Biolchi A; De Angelis G; Moschioni M; Tomei S; Brunelli B; Giuliani M; Bambini S; Borrow R; Claus H; Gorla MCO; Hong E; Lemos APS; Lucidarme J; Taha MK; Vogel U; Comanducci M; Budroni S; Giuliani MM; Rappuoli R; Pizza M; Boucher P Vaccine; 2020 Nov; 38(47):7542-7550. PubMed ID: 33036804 [TBL] [Abstract][Full Text] [Related]
29. Propositive follow-up: Long-term immune responses to the 4CMenB and MenACWY vaccines in people living with HIV. San Francisco Ramos A; Isitt C; Athaide S; Ladhani SN; Andrews NJ; Townsend-Payne K; Holland A; Louth J; Borrow R; Heath PT; Cosgrove CA HIV Med; 2024 Mar; 25(3):370-380. PubMed ID: 38013594 [TBL] [Abstract][Full Text] [Related]
30. Can we control all-cause meningococcal disease in Europe? Sadarangani M; Pollard AJ Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S103-S112. PubMed ID: 27129415 [TBL] [Abstract][Full Text] [Related]
31. Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands. Hepkema H; Pouwels KB; van der Ende A; Westra TA; Postma MJ PLoS One; 2013; 8(5):e65036. PubMed ID: 23741448 [TBL] [Abstract][Full Text] [Related]
32. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine. Tejedor JC; Merino JM; Moro M; Navarro ML; Espín J; Omeñaca F; García-Sicilia J; Moreno-Pérez D; Ruiz-Contreras J; Centeno F; Barrio F; Cabanillas L; Muro M; Esporrin C; De Torres MJ; Caubet M; Boutriau D; Miller JM; Mesaros N Pediatr Infect Dis J; 2012 Oct; 31(10):1074-7. PubMed ID: 22828645 [TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults. Beran J; Dražan D; Enweonye I; Bhusal C; Toneatto D mSphere; 2021 Dec; 6(6):e0055321. PubMed ID: 34787449 [TBL] [Abstract][Full Text] [Related]
34. Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and Meta-analysis. McMillan M; Chandrakumar A; Wang HLR; Clarke M; Sullivan TR; Andrews RM; Ramsay M; Marshall HS Clin Infect Dis; 2021 Aug; 73(3):e609-e619. PubMed ID: 33212510 [TBL] [Abstract][Full Text] [Related]
35. Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B Tsang RSW; Law DKS; De Paola R; Giuliani M; Stella M; Zhou J; Deng S; Boccadifuoco G; Giuliani MM; Serino L mSphere; 2020 Mar; 5(2):. PubMed ID: 32132156 [TBL] [Abstract][Full Text] [Related]
36. Meningococcal vaccination in patients with newly diagnosed asplenia in the United States. Ghaswalla PK; Bengtson LGS; Marshall GS; Buikema AR; Bancroft T; Schladweiler KM; Koep E; Novy P; Hogea CS Vaccine; 2021 Jan; 39(2):272-281. PubMed ID: 33309081 [TBL] [Abstract][Full Text] [Related]
37. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE; MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099 [TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L; Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171 [TBL] [Abstract][Full Text] [Related]
39. First Real-world Evidence of Meningococcal Group B Vaccine, 4CMenB, Protection Against Meningococcal Group W Disease: Prospective Enhanced National Surveillance, England. Ladhani SN; Campbell H; Andrews N; Parikh SR; White J; Edelstein M; Clark SA; Lucidarme J; Borrow R; Ramsay ME Clin Infect Dis; 2021 Oct; 73(7):e1661-e1668. PubMed ID: 32845996 [TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines. Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]